NT-proBNP in assessment of kidney dysfunction development in patients with diffuse large B-cell lymphoma receiving immune polychemotherapy

Autor: Anastasia S. Nozdricheva, Irina B. Lysenko, Nailya K. Guskova, Nadezhda V. Nikolaeva, Elena A. Kapuza, Anna V. Tishina, Tatiana F. Pushkareva, Svetlana V. Abakumova, Nadezhda V. Golomeeva, Olesya N. Selyutina, Natalia Yu. Samaneva, Inna A. Kamaeva, Zinaida P. Lisunova, Irina V. Tselishcheva, Svetlana V. Belgova, Viktoria R. Zakharchenko, Ineya I. Zekhtser, Liubov Yu Vladimirova, Aleksey N. Shevchenko, Sergey N. Dimitriadi
Rok vydání: 2022
Předmět:
Zdroj: Journal of Clinical Oncology. 40:e19554-e19554
ISSN: 1527-7755
0732-183X
Popis: e19554 Background: The purpose of this study was to assess NT-proBNP as a marker of renal dysfunction in patients with diffuse large B-cell lymphoma receiving immune polychemotherapy. Methods: The study involved 24 patients aged 23-69 years (median 57 years) with a primary diagnosis of diffuse large B-cell lymphoma (DLBCL). The renal status was assessed by the blood serum levels of creatinine, urea, NT-proBNP (Vitros 5600, USA), sodium (Cobas b221, Switzerland) with the calculation of the glomerular filtration rate (GFR) according to the CKD-EPI formula, as well as urine levels of albumin (Cobas Integra 400 plus, Switzerland). The tests were conducted before and 48 hours after induction immune polychemotherapy (R-CHOP). Statistical evaluation of results was made using the Statistica 13.0 program. Results: The patients were divided into 2 groups depending on the GFR levels before the start of therapy: group 1 (n = 16) - GFR 108.04±13.9 mL/min/1.73 m2 (normal levels); group 2 (n = 8) - GFR 59.57±12.04 mL/min/1.73m2 (reduced levels). The studied parameters in group 1 were within the reference values before treatment: NT-proBNP 109.38±13.6 pg/mL, creatinine 72.67±7.96 μmol/L, urea 5.39±0.99 mmol/L, albumin in urine 4.34±0.51 mg/L. After 48 hours, a moderate increase in NT-proBNP up to 207.5±48.2 pg/mL (p > 0.05) was observed, without significant changes in other parameters. In group 2, a pronounced increase in NT-proBNP was observed initially: 694±206.47 pg/mL, which was 5.6 times higher than the upper limit of the reference interval (p < 0.001) and 6.4 times higher than the levels in group 1 (p < 0.001), together with a significant increase in urine levels of albumin - 43.93±12.03 mg/L. Creatinine (80.67±4.35 μmol/L) and urea (6.4±1.41 mmol/L) remained within the reference range. After 48 hours, NT-proBNP increased by 3.8 times, reaching 2675±602.4 pg/mL (p < 0.001), which was accompanied by an increase in urine albumin - 57.8±8.86 mg/L and serum creatinine – 102.2±5.37 μmol/L in comparison with the initial levels. The levels of urea remained unchanged (6.6±0.43 mmol/L). The sodium levels did not differ significantly between the groups and was 141.65±2.24 mmol/L in group 1 and 140.85±3.4 mmol/L in group 2 and did not change over time. According to the results, patients with an initially decreased GFR demonstrated an increase in the levels of NT-proBNP and albumin in the urine even before the start of polychemotherapy. Conclusions: NT-proBNP can be considered an early marker of renal dysfunction in patients with diffuse large B-cell lymphoma.
Databáze: OpenAIRE
Externí odkaz: